{"title":"Carcinoma In Situ Skip Lesions of the Uterine Corpus in Cervical Squamous Cell Carcinoma: Impact on Target Setting in Radiotherapy","authors":"Mayumi Harada, Yasuhito Hagiwara, Takanobu Kabasawa, Hiraku Sato, Mayumi Ichikawa, Hiroko Akamatsu, Takashi Kaneko, Natsuko Yano, Ken Uematsu, Masanori Komatsu, Taiyo Tanae, Kenji Nemoto, Masashi Koto","doi":"10.1002/cnr2.70751","DOIUrl":"10.1002/cnr2.70751","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In definitive radiotherapy for FIGO Stage I–III cervical cancer, external beam radiotherapy and/or brachytherapy are used—alone or in combination with concurrent chemotherapy depending on stage—with target delineation largely guided by clinically apparent disease. However, discontinuous carcinoma in situ (CIS) “skip lesions” within the uterine corpus are well described in cervical adenocarcinoma, whereas their presence in cervical squamous cell carcinoma (SCC) has not been systematically evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to investigate the presence or absence of CIS skip lesions in the uterine corpus of patients with cervical SCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This retrospective study included all patients who underwent total or radical hysterectomy for cervical SCC at Yamagata University Hospital between January 2013 and April 2020. Patients who underwent prior radiotherapy or preoperative chemotherapy, or had non-squamous histological components, were excluded. Fifty patients were enrolled. Pathological examination of serially sectioned uterine specimens was conducted to identify skip lesions, defined as discontinuous CIS lesions in the uterine corpus, as confirmed by a pathologist and a radiation oncologist. Pathological evaluation showed that 29 patients (58%) had FIGO Stage I disease, 6 patients (12%) had FIGO Stage II disease, and 15 patients (30%) were classified as FIGO Stage IIIC1. Preoperative imaging studies did not identify any skip lesions in the uterine corpus. However, one patient (2%; Clopper–Pearson 95% confidence intervals: 0.05%–10.5%) presented with a histologically confirmed CIS skip lesion located in the uterine corpus, approximately 2 cm cranial to the primary tumor margin, that was undetectable on imaging. The primary tumor after biopsy measured 3 mm and was diagnosed as non-keratinizing SCC without > 1/3 stromal invasion. Lymphovascular space invasion, parametrial invasion, and corpus invasion were not observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although rare, CIS skip lesions in the uterine corpus can occur in patients with cervical SCC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 11","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70751","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sri Lanka Society of Gastroenterology Collaborative Hepatocellular Carcinoma Snapshot Audit (SLSG CARSA): A Nationwide, Cross-Sectional Snapshot Study","authors":"Madunil Anuk Niriella, Viranga Sathsarani Ranathunga, Sanduni Nirasha, Rohan Chaminda Siriwardana, Kuleesha Senarath Kodisinghe, Sujeewa Ravindu Kumarasena, Tharanga Liyanaarchchi, Suchintha Bandara Tillakaratne, Hasitha Wijewantha, Uditha Bandara Dassanayake, Vithiya Rishikesawan, Chamila Kumara Ranawaka, Anuradha Kajendran, Karthiha Balendran, Sanjeewa Aryasingha, Duminda Subasinghe, Nilesh Fernandopulle, Sudual Mananjala Senanayake, Anuradha Supun Dassanayake, Ishan de Zoysa, Chinthaka Viduranga de Silva, Chamila Subasinghe, Sumedha Udumalagala, Supun Kulathunga, Tilan Aponso, Vadivel Vijitharan, Isuru Upanishad, Nandana Dinamithra, Arunasalam Pathmeswaran, Hithanadura Janaka de Silva","doi":"10.1002/cnr2.70746","DOIUrl":"10.1002/cnr2.70746","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Sri Lanka lacks nationwide data on the incidence and characteristics of hepatocellular carcinoma (HCC); there is no prospective national HCC registry, and the only published clinical series comes from a single tertiary centre. We conducted a three-month, nationwide, snapshot cross-sectional survey to address this gap.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We invited clinicians at all state-sector and major private-sector institutions providing gastroenterology, gastrointestinal surgery, or oncology services in the nine provinces of Sri Lanka to report new cases diagnosed between June and August 2024. Diagnosis required either dynamic contrast-enhanced imaging in cirrhotic patients or histology in non-cirrhotic cases, or when imaging was inconclusive. We collected data on demographics, performance status, liver disease, risk factors, tumour characteristics and treatment approaches using a REDCap electronic case-report form with built-in validation and query resolution. Age-specific counts were multiplied by four to annualise the three-month observation and standardised to the WHO World Standard Population. Confidence intervals (CI) were derived from the observed (unannualised) case count, and sensitivity analyses examined seasonality and incomplete ascertainment. Apart from the incidence estimates, the analysis was descriptive, and no hypothesis testing was undertaken. The study is reported in accordance with STROBE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 140 patients were included. The age-standardised incidence rate was 2.51/100000 per year (95% CI 2.11–2.97; crude rate 2.54/100000, 95% CI 2.13–2.99). Most patients (78.6%) were male, with a mean age of 67.4 years. Key findings were as follows: the most frequently recorded risk factors were diabetes (66.4%) and unsafe alcohol use (62.9%); 85.7% had underlying cirrhosis, mostly Child-Turcotte-Pugh class A (62.5%); 43.8% presented with single nodules (<i>n</i> = 137), predominantly 2–5 cm (45.5%; <i>n</i> = 134); 16.4% showed tumour invasion and 12.9% had extra-hepatic spread; most cases were BCLC stages A (27.9%) or B (30.7%). No positive HBsAg or anti-HCV results were documented among those tested. Only 46.4% of cases were recorded as screen-detected, and an initial treatment decision was recorded for only 55.0% of cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This survey provides the first national estimate of HCC incidence in Sri Lanka, approximately twice the previous estimate. Because the earlier figure was der","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 11","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70746","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2026-11-04DOI: 10.1002/cnr2.70726
Neharika Bandaru, Job Shiach, Mark Agulnik
{"title":"Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST: A Case Report","authors":"Neharika Bandaru, Job Shiach, Mark Agulnik","doi":"10.1002/cnr2.70726","DOIUrl":"10.1002/cnr2.70726","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Gastrointestinal stromal tumors (GISTs) are commonly driven by activating mutations in <i>KIT</i> or <i>PDGFRA</i>. Although sequential tyrosine kinase inhibitors (TKIs) have improved outcomes in advanced disease, acquired resistance is common. Prospective studies of immune checkpoint blockade in GIST have shown limited activity, and immunotherapy is not a standard treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A man diagnosed at age 57 with epithelioid small-bowel GIST developed hepatic metastatic disease 7 years after his initial diagnosis. His tumor harbored a primary <i>KIT</i> exon 11 D579del mutation, a secondary <i>KIT</i> exon 17 D820G mutation, and <i>CDKN2A/CDKN2B</i> deletions; available molecular testing reported a low tumor mutational burden (1 mutation/Mb) and microsatellite-stable disease. After progression or treatment-limiting toxicity during six TKI regimens, pembrolizumab was initiated on October 28, 2025, when he was 76 years old, and administered intravenously every 3 weeks. The treatment has demonstrated stable disease on CT imaging; cycle 13 was then administered on July 28, 2026. No treatment delays or treatment-related adverse events were reported through cycle 13.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pembrolizumab was associated with at least 9 months of disease control in TMB-low, microsatellite-stable metastatic GIST after six TKI regimens. Because contemporaneous immune profiling and complete historical dosing data were unavailable, this observation is hypothesis-generating and does not establish that prior TKI exposure sensitized the tumor to PD-1 blockade.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 11","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13734685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2026-11-04DOI: 10.1002/cnr2.70738
Yuejin Sheng, Xiaoyu Dai, Jiaqi Lu, Hao Zhang, Ping Cai
{"title":"The Potential Role of Gut Microbiome Dysbiosis and Functional Reprogramming in Colorectal Liver Metastasis via the Gut–Liver Axis","authors":"Yuejin Sheng, Xiaoyu Dai, Jiaqi Lu, Hao Zhang, Ping Cai","doi":"10.1002/cnr2.70738","DOIUrl":"10.1002/cnr2.70738","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Colorectal liver metastasis (CRLM) is a leading cause of mortality in colorectal cancer (CRC), yet current surveillance often misses occult micrometastases, underscoring an urgent need for early non-invasive biomarkers and mechanistic insights.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to investigate gut microbiota dysbiosis and functional alterations associated with CRLM and explore potential non-invasive biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Fecal metagenomic sequencing was performed in 60 participants, comprising healthy controls, patients with non-metastatic CRC, and patients with synchronous CRLM (<i>n</i> = 20 per group). Microbial composition, functional pathways, co-occurrence networks, and clinical associations were systematically analyzed, and a random forest model was constructed to identify potential diagnostic biomarkers. Results showed that gut microbiota dysbiosis intensified as CRC progressed toward CRLM, characterized by the depletion of commensal flora and significant enrichment of specific genera, such as <i>Eikenella</i> and <i>Porphyromonas</i>. Functionally, the gut microbiome displayed stage-specific remodeling, shifting from infection- and virulence-related pathways in CRC to functions associated with microbial secondary metabolism and stress adaptation in CRLM. Furthermore, SPIEC-EASI-based network analysis revealed a sparser and more compartmentalized microbial ecological structure in CRLM, with <i>[Clostridium] symbiosum</i>, <i>Campylobacter concisus</i>, and <i>Coprococcus eutactus</i> emerging as module hubs. A random forest model integrating nine core taxa and one virulence factor (VF0160 <i>FeoAB</i>) achieved an overall 97.5% classification accuracy in discriminating CRLM from non-metastatic CRC, indicating the potential of fecal metagenomic biomarkers for future risk stratification. However, prospective validation in larger multicenter cohorts is required before clinical translational utility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Collectively, our findings suggest that gut microbiota dysbiosis and functional reprogramming are strongly associated with CRLM progression, potentially through remodeling the hepatic pre-metastatic niche via the gut-liver axis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 11","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13732294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2026-11-03DOI: 10.1002/cnr2.70725
Rider May Cedro, Gilton Marques Fonseca, Fabíola Trocoli Novaes, José Donizeti Meira Júnior, Vagner Birk Jeismann, Fabio Ferrari Makdissi, Jaime Arthur Pirolla Kruger, Fabricio Ferreira Coelho, Paulo Herman
{"title":"Inflammatory Markers and Outcomes After Liver Resection for Colorectal Liver Metastases","authors":"Rider May Cedro, Gilton Marques Fonseca, Fabíola Trocoli Novaes, José Donizeti Meira Júnior, Vagner Birk Jeismann, Fabio Ferrari Makdissi, Jaime Arthur Pirolla Kruger, Fabricio Ferreira Coelho, Paulo Herman","doi":"10.1002/cnr2.70725","DOIUrl":"https://doi.org/10.1002/cnr2.70725","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>The liver is the main site of colorectal metastatic disease. This study evaluated the association of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR) among patients with colorectal liver metastases (CRLM) undergoing liver resection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cohort of patients undergoing curative-intent liver resection for CRLM between 2009 and 2020 was evaluated. Association between inflammatory indices and overall survival (OS), disease-free survival (DFS), and postoperative morbidity and mortality were studied. Subgroup analyses included patients undergoing major hepatectomies (≥ 3 segments) and those receiving preoperative chemotherapy. The indices variation before and after chemotherapy were assessed for OS, DFS, and complete pathological response rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After exclusion criteria, 380 patients were selected for the study. No significant associations were found between inflammatory indices and OS or DFS. Lower preoperative PLR was associated with higher postoperative morbidity (<i>p</i> = 0.021) after major hepatectomies. Among patients receiving chemotherapy, a greater reduction in PLR was associated with a higher complete pathological response rate (<i>p</i> = 0.002).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although inflammatory indices were not predictive of survival outcomes, PLR was associated with postoperative morbidity and pathological response in specific subgroups; although these findings require validation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 11","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70725","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149311443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Combined Use of Clinician Prediction of Survival and the Palliative Prognostic Index for Short-Term Mortality Screening in Advanced Cancer Patients in an Acute Care Hospital","authors":"Tomoko Shiraishi, Megumi Kimura, Naomi Nabeshima, Asuka Ide, Takako Kondo, Kazue Hamada, Maya Akiyama, Tadanori Terada","doi":"10.1002/cnr2.70742","DOIUrl":"https://doi.org/10.1002/cnr2.70742","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In acute care oncology, timely recognition of short-term mortality risk is essential for initiating care planning, discharge coordination, and transition to palliative care. Clinician prediction of survival (CPS) is widely used in practice, but may fail to identify some patients at risk of death within weeks. This study evaluated the short-term mortality screening performance of CPS, the palliative prognostic index (PPI), and their combination among patients with advanced cancer transitioning to best supportive care (BSC), with particular emphasis on whether PPI could identify additional patients at risk of short-term mortality who were not identified by CPS alone.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single-center retrospective observational study screened adult patients with cancer referred to the palliative care team between April 2020 and November 2025. Patients who had transitioned to BSC were included in the primary analysis if a quantifiable CPS and a confirmed date of death were available. CPS was converted into survival days using predefined rules, and PPI was retrospectively assessed at the same index date. Diagnostic performance for death within 21 and 42 days was evaluated for CPS, PPI, and an “either-positive” combined rule. Receiver operating characteristic analyses and Kaplan–Meier analyses according to four CPS/PPI classification groups were also performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 750 patients referred to the palliative care team, 620 had transitioned to BSC and 357 were included in the primary analysis. Death within 21 and 42 days occurred in 158 (44.3%) and 237 (66.4%) patients, respectively. CPS and PPI yielded similar area under the curve (AUC) estimates for 21-day mortality (AUC, 0.732 vs. 0.742; <i>p</i> = 0.760) and 42-day mortality (0.727 vs. 0.731; <i>p</i> = 0.923). For 21-day mortality, sensitivity/specificity were 37.3%/89.4% for CPS, 58.9%/72.4% for PPI, and 72.2%/66.3% for the combined rule. For 42-day mortality, the corresponding values were 48.9%/78.3%, 73.4%/58.3%, and 82.3%/47.5%, respectively. Among patients who died within 21 and 42 days but were classified as negative by CPS, PPI additionally identified 55 of 99 (55.6%) and 79 of 121 (65.3%) patients, respectively. Among CPS-negative patients, Kaplan–Meier analyses showed significantly shorter survival in PPI-positive than in PPI-negative patients for both the 3- and 6-week classifications (log rank <i>p</i> < 0.001 for both). However, 25.0% and 42.4% of patients classified as negative by both measures died within 21 and 42 days, respectively.</p>\u0000 </section>\u0000 ","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 11","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70742","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149311249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2026-11-01DOI: 10.1002/cnr2.70745
Yi Guo, Zhen Li, Wenwei Song, Lansheng Zhang
{"title":"Development and Validation of Machine Learning Models Incorporating TGFBIp Expression for Prognosis Prediction in Epithelial Ovarian Cancer.","authors":"Yi Guo, Zhen Li, Wenwei Song, Lansheng Zhang","doi":"10.1002/cnr2.70745","DOIUrl":"10.1002/cnr2.70745","url":null,"abstract":"<p><strong>Background: </strong>Epithelial ovarian cancer (EOC) exhibits substantial heterogeneity in clinical outcomes, highlighting the need for diverse prognostic tools. Transforming growth factor-β-induced protein (TGFBIp) has been implicated in ovarian cancer progression, but its incremental prognostic value within machine learning frameworks remains unexplored.</p><p><strong>Aims: </strong>To develop and validate machine learning models incorporating TGFBIp expression to predict vital status and recurrence in EOC patients.</p><p><strong>Methods and results: </strong>We analyzed 155 EOC patients from a tissue microarray. TGFBIp expression in tumor cells and stroma was assessed by immunohistochemistry. Twelve machine learning algorithms were benchmarked across four feature inclusion strategies, with TGFBIp expression sequentially added to a baseline clinicopathological model. Model performance was assessed using the area under the receiver operating characteristic curve (AUC) with bootstrap 95% confidence intervals, the area under the precision-recall curve, calibration intercept and slope, Brier score, and decision curve analysis (DCA). The incremental value of TGFBIp was formally tested by paired bootstrap comparison of test-set AUCs. SHAP analysis was performed for model interpretation. The support vector machine (SVM) with Strategy 4 (incorporating both tumor and stromal TGFBIp) was selected for vital status prediction, achieving a test-set AUC of 0.951 (95% CI 0.870-0.998), accuracy of 0.872, sensitivity of 0.920, specificity of 0.818, and negative predictive value (NPV) of 0.900. The random forest (RF) with Strategy 4 was selected for recurrence prediction, achieving a test-set AUC of 0.936 (95% CI 0.816-1.000), sensitivity of 0.974, and NPV of 0.800. Adding TGFBIp features significantly improved vital status prediction (ΔAUC +0.038, 95% CI +0.002 to +0.092 for Strategy 4 vs. baseline). Calibration was acceptable for the vital status model (test-set calibration intercept -0.24, slope 1.25, Brier score 0.071). SHAP analysis identified maximum tumor diameter, grade, stage, and TGFBIp expression as leading predictors; tumoral TGFBIp contributed to both outcomes, whereas stromal TGFBIp contributed mainly to vital status prediction. DCA suggested potential clinical utility across a broad range of threshold probabilities.</p><p><strong>Conclusion: </strong>We established a machine learning framework incorporating compartment-specific TGFBIp expression for EOC prognosis. TGFBIp in tumor cells provided incremental prognostic information beyond conventional clinicopathological parameters.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 11","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13749431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2026-11-01DOI: 10.1002/cnr2.70749
Jing Yang, Ziyan Dong, Xinying Shi, Xin Luo, Jinfeng Cao
{"title":"Sarcomatoid Intrahepatic Cholangiocarcinoma With Well-Differentiated Squamous Cell Carcinoma Misdiagnosed as Liver Abscess: A Case Report.","authors":"Jing Yang, Ziyan Dong, Xinying Shi, Xin Luo, Jinfeng Cao","doi":"10.1002/cnr2.70749","DOIUrl":"10.1002/cnr2.70749","url":null,"abstract":"<p><strong>Background: </strong>Sarcomatoid intrahepatic cholangiocarcinoma (sICC) is a rare and highly aggressive variant of intrahepatic cholangiocarcinoma. Due to overlapping clinical and imaging features, it is frequently misdiagnosed as benign hepatic lesions, such as bacterial liver abscesses.</p><p><strong>Case: </strong>Herein, we report a case of a 59-year-old male patient who presented with fever and right upper abdominal pain. Laboratory tests revealed markedly elevated inflammatory markers. Ultrasound-guided percutaneous drainage was performed, and Hafnia alvei was cultured from the purulent fluid. Combined with abscess-like imaging manifestations and tumor necrosis with possible secondary infection, the case was preoperatively misdiagnosed as a bacterial liver abscess. The patient underwent a laparoscopic partial hepatectomy. Intraoperative frozen-section pathology suggested a hepatic malignant tumor, and the final postoperative diagnosis confirmed sICC with well-differentiated squamous cell carcinoma. Despite aggressive surgical intervention, the patient's condition rapidly deteriorated with imaging suggestive of tumor progression, and he died of multiple organ failure approximately 10 weeks after the initial surgery.</p><p><strong>Conclusion: </strong>This case underscores the diagnostic pitfall of sICC presenting as a liver abscess. Puncture or drainage of such necrotic masses should be performed with caution due to the risk of tumor cell dissemination. Early recognition, timely biopsy, and aggressive radical resection are crucial for improving the prognosis of this rare entity.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 11","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13745802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2026-11-01DOI: 10.1002/cnr2.70729
Minlian Nong, Xiang Tan
{"title":"Long-Term Recurrence-Free Survival After Surgery and Adjuvant Furmonertinib in a Patient With EGFR-Mutated Pulmonary Sarcomatoid Carcinoma: A Case Report.","authors":"Minlian Nong, Xiang Tan","doi":"10.1002/cnr2.70729","DOIUrl":"10.1002/cnr2.70729","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare subtype of non-small cell lung cancer (NSCLC), which generally shows limited response to chemoradiotherapy and confers poor overall survival (OS). Recent progress in molecular targeted therapy has provided potential therapeutic strategies for this disease. Herein, we report a rare case of PSC harboring concurrent EGFR L858R and PIK3CA exon 10 mutations. The patient underwent radical surgical resection followed by adjuvant third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted therapy, and sustained long-term disease-free survival (DFS) was observed during clinical follow-up. Although this case showed a favorable outcome, causality cannot be established from a single case report. Whether adjuvant furmonertinib contributed to the long-term DFS remains uncertain and requires further investigation.</p><p><strong>Case: </strong>A middle-aged female presented with cough, expectoration, and hemoptysis. Percutaneous lung biopsy confirmed Stage IIIA pulmonary sarcomatoid carcinoma, and radical surgical resection was subsequently performed. Postoperative next-generation sequencing identified concomitant EGFR L858R and PIK3CA exon 10 mutations. The patient received adjuvant furmonertinib as postoperative targeted therapy. No tumor recurrence was detected throughout follow-up, with a documented DFS of 48 months.</p><p><strong>Conclusion: </strong>Surgical resection remains the primary treatment for patients with early-stage PSC, and postoperative molecular testing is critical to identify targetable mutations. This patient obtained durable DFS after radical resection combined with adjuvant third-generation EGFR-TKI targeted therapy. Additional large-scale studies are needed to confirm the efficacy of adjuvant EGFR-TKIs in PSC patients with dual EGFR/PIK3CA mutations.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 11","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13756584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer reportsPub Date : 2026-11-01DOI: 10.1002/cnr2.70728
Helal Metwalli, Mohammad Najm Dadam, Lam Ngoc Tram, Tuan Vu Nguyen, Tran Quoc Huy, Tran Cong Duy Long, Nguyen Tien Huy
{"title":"The Hidden Burden: Addressing Disparities in Childhood Cancer Incidence Trends.","authors":"Helal Metwalli, Mohammad Najm Dadam, Lam Ngoc Tram, Tuan Vu Nguyen, Tran Quoc Huy, Tran Cong Duy Long, Nguyen Tien Huy","doi":"10.1002/cnr2.70728","DOIUrl":"10.1002/cnr2.70728","url":null,"abstract":"<p><strong>Background: </strong>Childhood cancer incidence and survival vary substantially worldwide, with major disparities between high- and low and middle-income countries (HICs and LMICs). This review synthesizes global disparities in incidence, survival, and the factors contributing to inequity.</p><p><strong>Recent findings: </strong>Childhood cancer incidence has increased in several regions, but trends vary geographically. Major disparities persist in registry coverage, diagnosis, stage at presentation, treatment access, and survival, with 5-year survival exceeding 80% in most HICs but remaining below 30% in many LMICs.</p><p><strong>Conclusion: </strong>Global disparities reflect interacting socioeconomic, environmental, genetic, and health-system factors, compounded by substantial data gaps and inconsistent surveillance. Strengthening cancer registries, standardizing classification and staging, expanding equitable cancer care, and prioritizing multinational research are essential to reduce these inequities.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 11","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13756581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}